MedTrace Logo

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

NCT07221708 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-01-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics.

Participants in this study will be placed randomly into two groups. The oral vancomycin treatment group will receive oral vancomycin two times per day simultaneously with an antibiotic plus two additional days. The no oral vancomycin control group will receive the current standard of care, which is an antibiotic and no oral vancomycin. Participation in this study will last approximately 3 months.

Conditions

  • Clostridioides Difficile
  • Vancomycin Resistance Enterococcus Faecium

Interventions

DRUG

Vancomycin (POC)

A dosage of oral vancomycin 125 mg will be given twice daily for the duration of the concomitant antibiotic plus two additional days

Sponsors & Collaborators

  • University of Maryland, Baltimore Washington Medical Center

    collaborator UNKNOWN

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Jeffrey Marshall, MD · University of Maryland, Baltimore Washington Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07221708 on ClinicalTrials.gov